Efficacy and safety of bazedoxifene, a novel selective estrogen receptor modulator for the prevention and treatment of postmenopausal osteoporosis

References

• North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause 2006;13:340-67
   PubMed Web of Science ®Google Scholar
• Dennison E, Cooper C. Epidemiology of osteoporotic fractures. Horm Res 2000;54:58-63
   PubMed Web of Science ®Google Scholar
• NIH Consensus Development Panel. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
   PubMed Web of Science ®Google Scholar
• Delaney MF. Strategies for the prevention and treatment of osteoporosis during early postmenopause. Am J Obstet Gynecol 2006;194:S12-23
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Vacca F. Postmenopausal osteoporosis and hormone replacement therapy. Minerva Med 2004;95:507-20
   PubMedGoogle Scholar
• Caliri A, De Filippis L, Bagnato GL, et al. Osteoporotic fractures: mortality and quality of life. Panminerva Med 2007;49:21-7
   PubMed Web of Science ®Google Scholar
• Desai SS, Duncan BS, Sloan AS. The cost of treating osteoporosis in a managed health care organization. J Manag Care Pharm 2003;9:142-9
   PubMedGoogle Scholar
• Gold DT. The nonskeletal consequences of osteoporotic fractures. Psychologic and social outcomes. Rheum Dis Clin North Am 2001;27:255-62
   PubMed Web of Science ®Google Scholar
• Salaffi F, Cimmino MA, Malavolta N, et al. The burden of prevalent fractures on health-related quality of life in postmenopausal women with osteoporosis: the IMOF study. J Rheumatol 2007;34:1551-60
   PubMed Web of Science ®Google Scholar
• MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 2008;148:197-213
   PubMed Web of Science ®Google Scholar
• McClung MR. Bisphosphonates. Endocrinol Metab Clin North Am 2003;32:253-71
   PubMed Web of Science ®Google Scholar
• Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. J Clin Endocrinol Metab 2000;85:4118-24
   PubMed Web of Science ®Google Scholar
• Delmas PD, Recker RR, Chesnut CH III, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int 2004;15:792-8
   PubMed Web of Science ®Google Scholar
• Hooper MJ, Ebeling PR, Roberts AP, et al. Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebo-controlled trial. Climacteric 2005;8:251-62
   PubMed Web of Science ®Google Scholar
• McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333-40
   PubMed Web of Science ®Google Scholar
• Ravn P, Weiss SR, Rodriguez-Portales JA, et al. Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group. J Clin Endocrinol Metab 2000;85:1492-7
   PubMed Web of Science ®Google Scholar
• Stakkestad JA, Benevolenskaya LI, Stepan JJ, et al. Intravenous ibandronate injections given every three months: a new treatment option to prevent bone loss in postmenopausal women. Ann Rheum Dis 2003;62:969-75
   PubMed Web of Science ®Google Scholar
• Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA 1999;282:1344-52
   PubMed Web of Science ®Google Scholar
• Cranney A, Guyatt G, Griffith L, et al. Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev 2002;23:570-8
   PubMed Web of Science ®Google Scholar
• Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf 2007;30:755-63
   PubMed Web of Science ®Google Scholar
• Grey A, Reid IR. Differences between the bisphosphonates for the prevention and treatment of osteoporosis. Ther Clin Risk Manag 2006;2:77-86
   PubMedGoogle Scholar
• Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med 2009;122:S33-45
   PubMed Web of Science ®Google Scholar
• Khosla S, Burr D, Cauley J, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007;22:1479-91
   PubMed Web of Science ®Google Scholar
• Department of Health and Human Services, Public Health Service, Food and Drug Administration. ODS Postmarketing Safety Review. FDA osteonecrosis statement. 2004
   Google Scholar
• Bobba RS, Beattie K, Parkinson B, et al. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006;29:1133-52
   PubMed Web of Science ®Google Scholar
• Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653-61
   PubMed Web of Science ®Google Scholar
• Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006;54:1838-46
   PubMed Web of Science ®Google Scholar
• Gass M. Highlights from the latest WHI publications and the latest North American Menopause Society position statement on use of menopausal hormone therapy. Cleve Clin J Med 2008;75:S13-16
   PubMedGoogle Scholar
• Lobo RA, Belisle S, Creasman WT, et al. Should symptomatic menopausal women be offered hormone therapy?. MedGenMed 2006;8:40
   PubMedGoogle Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-13
   PubMed Web of Science ®Google Scholar
• Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
   PubMed Web of Science ®Google Scholar
• Vickers MR, Maclennan AH, Lawton B, et al. Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ 2007;335:239
   PubMed Web of Science ®Google Scholar
• North American Menopause Society. Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause 2008;15:584-602
   PubMed Web of Science ®Google Scholar
• Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434-41
   PubMed Web of Science ®Google Scholar
• Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 2005;26:688-703
   PubMed Web of Science ®Google Scholar
• Chesnut CHI, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000;109:267-76
   PubMed Web of Science ®Google Scholar
• Cole Z, Dennison E, Cooper C. Update on the treatment of post-menopausal osteoporosis. Br Med Bull 2008;86:129-43
   PubMed Web of Science ®Google Scholar
• Marie PJ, Ammann P, Boivin G, Rey C. Mechanisms of action and therapeutic potential of strontium in bone. Calcif Tissue Int 2001;69:121-9
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459-68
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Boivin G, Marie PJ. About the comparison of two anabolic agents, teriparatide and strontium ranelate, in treated osteoporotic women. J Bone Miner Res 2009;24:2066-8
   PubMed Web of Science ®Google Scholar
• Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab 2005;90:2816-22
   PubMed Web of Science ®Google Scholar
• Reginster JY, Felsenberg D, Boonen S, et al. Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial. Arthritis Rheum 2008;58:1687-95
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641-7
   PubMed Web of Science ®Google Scholar
• Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 2002;87:3609-17
   PubMed Web of Science ®Google Scholar
• Johnston CC Jr, Bjarnason NH, Cohen FJ, et al. Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials. Arch Intern Med 2000;160:3444-50
   PubMed Web of Science ®Google Scholar
• Jolly EE, Bjarnason NH, Neven P, et al. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years. Menopause 2003;10:337-44
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999;282:637-45
   PubMed Web of Science ®Google Scholar
• Delmas PD, Genant HK, Crans GG, et al. Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial. Bone 2003;33:522-32
   PubMed Web of Science ®Google Scholar
• Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study. J Bone Miner Res 2005;20:1514-24
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 1999;281:2189-97
   PubMed Web of Science ®Google Scholar
• Aldrighi JM, Quail DC, Levy-Frebault J, et al. Predictors of hot flushes in postmenopausal women who receive raloxifene therapy. Am J Obstet Gynecol 2004;191:1979-88
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 2006;355:125-37
   PubMed Web of Science ®Google Scholar
• Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin 2005;21:1441-52
   PubMed Web of Science ®Google Scholar
• Stovall DW, Utian WH, Gass ML, et al. The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety. Menopause 2007;14:510-17
   PubMed Web of Science ®Google Scholar
• Davies GC, Huster WJ, Lu Y, et al. Adverse events reported by postmenopausal women in controlled trials with raloxifene. Obstet Gynecol 1999;93:558-65
   PubMed Web of Science ®Google Scholar
• Mosca L, Grady D, Barrett-Connor E, et al. Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease. Stroke 2009;40:147-55
   PubMed Web of Science ®Google Scholar
• Bushardt RL, Turner JL, Ragucci KR, Askins DG Jr. Non-estrogen treatments for osteoporosis: an evidence-based review. JAAPA 2006;19:25-30
   PubMedGoogle Scholar
• Palacios S. The future of the new selective estrogen receptor modulators. Menopause Int 2007;13:27-34
   PubMedGoogle Scholar
• Arun B, Anthony M, Dunn B. The search for the ideal SERM. Expert Opin Pharmacother 2002;3:681-91
   PubMedGoogle Scholar
• Shelly W, Draper MW, Krishnan V, et al. Selective estrogen receptor modulators: an update on recent clinical findings. Obstet Gynecol Surv 2008;63:163-81
   PubMed Web of Science ®Google Scholar
• Taylor HS. Designing the ideal selective estrogen receptor modulator – an achievable goal?. Menopause 2009;16:609-15
   PubMed Web of Science ®Google Scholar
• Komm BS, Lyttle CR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci 2001;949:317-26
   PubMed Web of Science ®Google Scholar
• Lewiecki EM. Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis. Expert Opin Investig Drugs 2007;16:1663-72
   PubMed Web of Science ®Google Scholar
• Musa MA, Khan MO, Cooperwood JS. Medicinal chemistry and emerging strategies applied to the development of selective estrogen receptor modulators (SERMs). Curr Med Chem 2007;14:1249-61
   PubMed Web of Science ®Google Scholar
• Miller CP, Collini MD, Tran BD, et al. Design, synthesis, and preclinical characterization of novel, highly selective indole estrogens. J Med Chem 2001;44:1654-7
   PubMed Web of Science ®Google Scholar
• Komm BS, Kharode YP, Bodine PV, et al. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology 2005;146:3999-4008
   PubMed Web of Science ®Google Scholar
• Peano BJ, Crabtree JS, Komm BS, et al. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology 2009;150:1897-903
   PubMed Web of Science ®Google Scholar
• Ermer J, McKeand W, Sullivan P, et al. Bazedoxifene acetate dose proportionality in healthy, postmenopausal women [abstract]. Clin Pharmacol Ther 2003;73:P46
   Web of Science ®Google Scholar
• Chandrasekaran A, McKeand WE, Sullivan P, et al. Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women. Drug Metab Dispos 2009;37:1219-25
   PubMed Web of Science ®Google Scholar
• Ronkin S, Clarke L. TSE-424, a novel tissue selective estrogen, reduces biochemical indices of bone metabolism in a dose related fashion [abstract SU437]. J Bone Miner Res 2001;16(Suppl 1):S413
   Google Scholar
• Ronkin S, Northington R, Baracat E, et al. Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet Gynecol 2005;105:1397-404
   PubMed Web of Science ®Google Scholar
• Miller PD, Chines AA, Christiansen C, et al. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study. J Bone Miner Res 2008;23:525-35
   PubMed Web of Science ®Google Scholar
• Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J Bone Miner Res 2008;23:1923-34
   PubMed Web of Science ®Google Scholar
• Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone 2009;44:1049-54
   PubMed Web of Science ®Google Scholar
• Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of Osteoporosis at the Primary Health Care Level 2008 World Health Organization Collaborating Centre for Metabolic Bone Diseases, Sheffield, UK. Technical report
   Google Scholar
• Kanis JA, Johnell O, Oden A, et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int 2008;19:385-97
   PubMed Web of Science ®Google Scholar
• McCloskey E, Johansson H, Oden A, et al. 2009 Assessment of the effect of bazedoxifene on non-vertebral fracture risk. J Bone Miner Res 24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=6c55b263-692e-4a37-b807-f7a153641564. Accessed October 26, 2009
   Google Scholar
• McCloskey EV, Johansson H, Oden A, et al. Ten-year fracture probability identifies women who will benefit from clodronate therapy – additional results from a double-blind, placebo-controlled randomised study. Osteoporos Int 2009;20:811-17
   PubMed Web of Science ®Google Scholar
• Silverman S, Chines A, Zanchetta JR, et al. 2009 Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. J Bone Miner Res 24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2643ea2f-c4ab-4eb6-9798-09050bb21b6b. Accessed October 15, 2009
   Google Scholar
• de Villiers TJ, Kendler D, Chines A, et al. 2009 Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. J Bone Miner Res 24(Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1dae18c8-99a0-4757-957b-689b21823623. Accessed October 15, 2009
   Google Scholar
• Silverman S, Chines A, Zanchetta JR, et al. 2009 Sustained efficacy of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study. J Bone Miner Res 24 (Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=2643ea2f-c4ab-4eb6-9798-09050bb21b6b. Accessed October 15, 2009
   Google Scholar
• de Villiers TJ, Kendler D, Chines A, et al. 2009 Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled phase 3 trial. J Bone Miner Res 24 (Suppl 1). Available at: http://www.asbmr.org/Meetings/AnnualMeeting/AbstractDetail.aspx?aid=1dae18c8-99a0-4757-957b-689b21823623. Accessed October 15, 2009
   Google Scholar
• Fleischer AC, Wheeler JE, Yeh IT, et al. Sonographic assessment of the endometrium in osteopenic postmenopausal women treated with idoxifene. J Ultrasound Med 1999;18:503-12
   PubMed Web of Science ®Google Scholar
• Goldstein SR, Nanavati N. Adverse events that are associated with the selective estrogen receptor modulator levormeloxifene in an aborted phase III osteoporosis treatment study. Am J Obstet Gynecol 2002;187:521-7
   PubMed Web of Science ®Google Scholar
• Pinkerton JV, Archer DF, Utian WH, et al. Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. Menopause 2009;16:1102-8
   PubMed Web of Science ®Google Scholar
• Archer DF, Pinkerton JV, Utian WH, et al. Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women. Menopause 2009;16:1109-15
   PubMed Web of Science ®Google Scholar
• Palacios S, Menegoci JC, Kelepouris N, et al. Endometrial and breast safety of bazedoxifene in postmenopausal women with osteoporosis: findings from a 5-year, randomized, placebo-controlled phase 3 trial [abstract]. Menopause 2009;16:1263
   Web of Science ®Google Scholar
• Harvey JA, Holm MK, Ranganath R, et al. The effects of bazedoxifene on mammographic breast density in postmenopausal women with osteoporosis. Menopause 2009;16:1193-6
   PubMed Web of Science ®Google Scholar
• Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril 2009;92:1045-52
   PubMed Web of Science ®Google Scholar
• Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril 2009;92:1025-38
   PubMed Web of Science ®Google Scholar
• Pickar JH, Yeh I-T, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril 2009;92:1018-24
   PubMed Web of Science ®Google Scholar
• Archer DF, Lewis V, Carr BR, et al. Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. Fertil Steril 2009;92:1039-44
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis [online]. Available at: http://www.nof.org/professionals/Clinicians_Guide.htm. Accessed October 28, 2009
   Google Scholar
• Compston J. Clinical and therapeutic aspects of osteoporosis. Eur J Radiol 2009;71:388-91
   PubMed Web of Science ®Google Scholar
• Gruber C, Gruber D. Bazedoxifene (Wyeth). Curr Opin Investig Drugs 2004;5:1086-93
   PubMedGoogle Scholar
• Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002;359:1929-36
   PubMed Web of Science ®Google Scholar